ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
ImmunityBio (NASDAQ: IBRX) has announced its 2024 Annual Meeting of Stockholders, scheduled for June 11, 2024, at 9:30 a.m. PT. The meeting will be held virtually with no physical location. Shareholders of record as of April 17, 2024, are eligible to vote and participate.
Chief Executive Officer Richard Adcock will provide a business update following the formal business proceedings. Non-shareholders can join the virtual meeting as guests. A replay will be available within 24 hours on the company's investor relations website and remain accessible for 90 days.
Additional presentations and webcasts on company developments can also be found on the investor relations site, which may contain material information.
- Announcement of the 2024 Annual Meeting, providing transparency and engagement opportunities for shareholders.
- Virtual format increases accessibility for all interested parties.
- Replay availability for 90 days ensures comprehensive access to information.
- CEO Richard Adcock will provide a business update, suggesting transparency and upcoming developments.
- Virtual-only format might limit interaction and engagement compared to in-person meetings.
- No specific financial or clinical data updates were provided in this announcement.
Richard Adcock, the Company’s Chief Executive Officer and President, will provide a business update after the formal business of the Annual Meeting has ended. All interested parties are welcome to attend the Annual Meeting and listen to the Company update. Non-stockholders can attend the virtual Annual Meeting by using the following link: virtualshareholdermeeting.com/IBRX2024 and clicking on the “GUEST” button to join the meeting. This website will available 15 minutes prior to the start of the Annual Meeting.
A playback of this event will be available for replay within 24 hours after the completion of the Annual Meeting at ir.immunitybio.com/ for at least 90 days after the event.
Availability of Other Information about ImmunityBio, Inc.
A playback of this event, along with other selected webcasts and presentations regarding developments in the Company’s business given by management at certain investor and medical conferences, can be found on the Company’s Investor Relations website, ir.immunitybio.com, under “CompanyꟷEvents & Presentations.” The information posted on this website could be deemed to be material information. As a result, investors, the media, and others interested in ImmunityBio are encouraged to review this information on a regular basis. The contents of the Company’s websites, or any other website that may be accessed from the Company’s website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
About ImmunityBio
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer that activates natural killer cells, T cells, and memory T cells for a long duration response. The company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
For more information, please visit: www.immunitybio.com
Forward-Looking Statements
This press release and the event referenced herein may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding anticipated event timing and content, data and results from clinical trials and potential implications therefrom, commercialization plans and timelines, including product availability and shipments, potential regulatory pathways and approval requests and submissions, FDA meetings, timelines and potential results therefrom, the regulatory review process and timing thereof, market and prevalence data, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, information regarding ongoing pre-clinical studies and clinical trials, potential future uses and applications of ANKTIVA and use in cancer vaccines and across multiple tumor types, ImmunityBio’s financial condition, and ImmunityBio’s approved product and investigational agents as compared to existing treatment options, among others. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) the risks and uncertainties associated with commercial launch execution, success and timing, (ii) risks and uncertainties related to the regulatory submission and review process, (iii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) potential delays in product availability and regulatory approvals, (v) risks and uncertainties associated with third party collaborations and agreements, (vi) whether the BCG manufactured by Serum Institute of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240607246847/en/
Investors
Hemanth Ramaprakash, PhD, MBA
ImmunityBio, Inc.
+1 858-746-9289
Hemanth.Ramaprakash@ImmunityBio.com
Media
Greg Tenor
Salutem
+1 717-919-6794
Gregory.Tenor@Salutemcomms.com
Source: ImmunityBio, Inc.
FAQ
When is ImmunityBio's 2024 Annual Meeting of Stockholders?
How can shareholders participate in ImmunityBio's 2024 Annual Meeting?
Can non-shareholders attend the ImmunityBio 2024 Annual Meeting?
Will there be a business update during the ImmunityBio 2024 Annual Meeting?